•  
  •  
 

The Thai Journal of Pharmaceutical Sciences

Abstract

It has been clearly established that getting the coronavirus disease 2019 (COVID-19) vaccination reduces the risk of serious illness, hospitalization, and even death. Although, since vaccines are not 100% effective at preventing infection, some people who are fully vaccinated will still get COVID-19. This report presents the event of COVID-19 infection following third-dose booster of mRNA COVID-19 vaccination in a Thai female patient with spondyloarthritis, whose disease was well controlled by methotrexate, sulfasalazine and indomethacin. She got a full course of inactivated COVID-19 vaccine (Sinovac-CoronaVac vaccine) and one booster shot of messenger RNA (mRNA) COVID-19 vaccine (Pfizer-BioNTech). Around three months after a booster dose, the patient complained of mild rhinitis and the positive result for COVID-19 via an antigen test kit (ATK) was presented. According to the powerful immunosuppressive effects of methotrexate, we presume that this drug may impair immune responses that could potentially lead to breakthrough SARS-CoV-2 infection. Therefore, the patients and healthcare providers should be concerned about the appropriate duration of methotrexate cessation on an individual basis in order to improve the immune response to vaccinations, especially for pandemic and epidemic-prone diseases, e.g. COVID-19.

DOI

10.56808/3027-7922.2794

Download

Share

COinS